Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.

Saglam S., Hacisahinogullari H., Ozturk N., Kapran Y., Gulluoglu M., Turkmen C., ...Daha Fazla

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.20, sa.5, ss.1201-5, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 5
  • Basım Tarihi: 2015
  • Dergi Adı: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1201-5
  • Anahtar Kelimeler: gastroentero pancreatic neuroendocrine tumor, LAR, non-functioning tumor, octreotide, survival, SOMATOSTATIN ANALOGS, LANREOTIDE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose: Benefits of somatostatin analogues have been mostly studied in mixed samples of patients including both functional and non-functional neuroendocrine tumors. This study aimed to examine the response of patients with non-functional metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that received first-line treatment with the somatostatin analogue octreotide LAR.